INTRODUCTION
Passive administration of antibodies directed against the envelope protein (Env) of HIV-1 represents a promising mode of clinical intervention for this disease as a result of the recent isolation and characterization of human antibodies with exceptionally broad and potent neutralizing activity Scheid et al., 2009; Walker et al., 2011) . Passive administration of these anti-HIV-1 broadly neutralizing antibodies (bNAbs) has been shown to confer sterilizing immunity against virus containing elements of HIV and SIV (SHIV) challenge in macaques and HIV-1 infection in humanized mouse models (Balazs et al., 2012; Hessell et al., 2007; Mascola et al., 2000) . Furthermore, effective control of viral replication in HIV-1-infected humanized mice and in SHIV-infected nonhuman primates by bNAbs clearly suggested their potential use as a therapeutic modality for human HIV-1 infection (Barouch et al., 2013; Horwitz et al., 2013; Klein et al., 2012b; Shingai et al., 2013) .
Although the neutralizing activity of an antibody has been commonly considered to be the result of Fab-antigen interactions that block viral entry, substantial evidence suggests that the in vivo activity of an antibody is highly dependent upon interactions of the immunoglobulin G (IgG) fragment crystallizable (Fc) domain with its cognate receptors, Fcg receptors (FcgR) expressed on the surface of effector leukocytes (Abboud et al., 2010; Corti et al., 2011; DiLillo et al., 2014; Li and Ravetch, 2011; Nimmerjahn and Ravetch, 2005; Smith et al., 2012) . The FcgR system represents a balance of activating and inhibitory receptors that transduce immunostimulatory or immunomodulatory signals following engagement with IgG immune complexes, determining thereby the outcome of IgG-mediated inflammation and immunity (Pincetic et al., 2014) . Indeed, selective engagement of activating or inhibitory FcgRs by IgG has been shown to determine the in vivo outcome of antibody treatment, suggesting that Fc-mediated pathways play a key role in modulating the effector activity of a monoclonal antibody (mAb) (Li and Ravetch, 2011; Nimmerjahn and Ravetch, 2005) . For example, the neutralizing activity of antitoxin and antiviral antibodies has been demonstrated to require selective FcgR engagement to mediate their in vivo protective activities (Akiyoshi et al., 2010; Corti et al., 2011; DiLillo et al., 2014) .
Although the potential involvement of FcgR effector pathways in antibody-mediated protection against HIV-1 has been previously discussed in numerous studies (Ackerman et al., 2013; Forthal et al., 2010 Forthal et al., , 2011 Lai et al., 2014; Perez et al., 2013) , there is still very limited evidence on the exact contribution of Fc effector function in the protective activity of anti-HIV-1 mAbs, stemming from the lack of an in vivo model system that recapitulates FcgR functional and structural diversity. Indeed, the use of artificial in vitro systems for the study of Fc effector function poorly reflects the diversity and complexity of in vivo FcgR-mediated pathways, providing thereby limited information on the precise Fc effector mechanisms that mediate viral neutralization in vivo. To assess the contribution of Fc-mediated interactions in the in vivo activity of anti-HIV-1 bNAbs, we utilized recently developed mouse models for HIV-1 entry (Pietzsch et al., 2012) and infection (Baenziger et al., 2006; Klein et al., 2012b; Traggiai et al., 2004) . These models have been previously characterized extensively and used to successfully assess the capacity of several anti-HIV-1 bNAbs to inhibit HIV-1 entry (Pietzsch et al., 2012) or suppress viremia in vivo (Horwitz et al., 2013; Klein et al., 2012b) . Furthermore, the immunotherapeutic potential of anti-HIV-1 bNAbs against HIV-1 infection in these murine infection models has been shown to correlate with nonhuman primates (Barouch et al., 2013; Shingai et al., 2013) , supporting their use for the preclinical evaluation of anti-HIV-1 bNAbs intended for human HIV-1 prevention or therapy.
In the present study, we assessed the role of Fc effector function in the in vivo protective activity of several anti-HIV-1 bNAbs targeting different epitopes on the HIV-1 Env protein. We found that FcgR-mediated effector function contributes significantly to their in vivo activity and clearly demonstrated that preferential engagement of activating FcgRs substantially augmented the in vivo protective activity of anti-HIV-1 bNAbs. Fc domain engineering of anti-HIV-1 bNAbs to selectively enhance their capacity to interact with activating FcgRs resulted in a substantial augmentation of their in vivo activity when assessed in an in vivo model of HIV-1 entry (Pietzsch et al., 2012) , as well as in models of mAb-mediated therapy using HIV-1-infected humanized mice.
RESULTS

Generation and Characterization of Mouse-Human
Chimeric Anti-HIV-1 bNAbs for the Study of In Vivo Fc Effector Activity Because the binding specificity of the Fc region to the respective FcgRs is species specific, we generated mouse-human chimeric versions of several anti-HIV-1 bNAbs in which the constant region of the heavy chain (CH1-3; human IgG1) was replaced with that of different mouse IgG Fc subclass variants that exhibit differential and selective binding capacity for activating or inhibitory mouse FcgRs ( Figure 1A and Table S1 available online) (Nimmerjahn and Ravetch, 2005) . This approach has been previously exploited to dissect the individual contribution of activating or inhibitory FcgR-mediated pathways in the in vivo activity of protective and immunomodulatory antibodies Li and Ravetch, 2011) . We have additionally generated a mouse IgG1 variant (D265A) with diminished binding to all classes of FcgRs for the assessment of Fc effector function in the in vivo anti-HIV-1 bNAb activity.
A number of anti-HIV-1 bNAbs were selected targeting various epitopes of HIV-1 Env, exhibiting variable degree of in vitro neutralization breadth and potency (Table S3 and Figure 1D ). These included the anti-CD4 binding site (CD4bs) monoclonal antibodies (mAbs) 3BNC117 Figure S1 . (D) In vitro neutralization activity of mouse-human anti-HIV-1 mAbs against HIV-1 YU-2 was determined by a standardized TZM-bl assay (Montefiori, 2005) , and IC 50 values are presented (see also  Table S3 ).
mAb recognizing a conformational V3/CD4i epitope (Klein et al., 2012a) ; PG16, an anti-V1/2 mAb (Walker et al., 2009) ; and the anti-V3 mAbs 1-79 (Scheid et al., 2009 ) and PGT121 Walker et al., 2011) . A non-HIV-1 reactive mAb (mGO53 [Wardemann et al., 2003] ) was included as control. Mouse-human chimeric mAbs were expressed in mammalian cells (HEK293T cells) and characterized in terms of antigen specificity by ELISA ( Figure S1 ), by surface plasmon resonance (Figure 1B and Table S2 ) using recombinant gp140, and by flow cytometry using gp160-expressing cells (gp160Dct [deleted cytoplasmic tail]-HEK293T cells) ( Figure 1C ) to ensure that changes in the Fc domain had no impact on their capacity for Fab-mediated antigen recognition, an effect that was previously described for other (not anti-HIV-1) mAbs (Casadevall and Janda, 2012) . Although these mouse Fc domain variants exhibited differential capacity to engage mouse FcgRs (Table S1 and Figure 1A ), no differences in their antigen affinity and specificity were observed. Furthermore, no differences in the in vitro neutralization activity were evident among the various mouse IgG subclass variants (Table S3 and Figure 1D ).
The In Vivo Protective Activity of Anti-HIV-1 bNAbs Is Dependent upon FcgR Engagement Given the differential capacity of the mouse-human chimeric IgG subclass variants of anti-HIV-1 bNAbs to engage particular classes of FcgRs, comparison of their in vivo activity would determine the specific contribution of particular FcgR classes required for optimal mAb in vivo function. Using a recently described mouse model of HIV-1 entry (Pietzsch et al., 2012) that is based on a principle closely related to the well-established in vitro TZM-bl neutralization assay (Montefiori, 2005) , we assessed the in vivo activity of the various mouse subclass variants of anti-HIV-1 bNAbs. As determined previously (Pietzsch et al., 2012) , in vivo infection of luciferase reporter mice (ROSA-Luc) with HIV-1 Cre pseudovirus was accomplished by administration of adenoviral particles (10 11 , intravenous [i.v.] , 48 hr prior to HIV-1 YU-2 Cre pseudovirus challenge) coding for the receptors required for HIV-1 entry (hCD4 and hCCR5) ( Figure 2A ). Following challenge with HIV-1 Cre pseudovirus, infection was quantified noninvasively by whole-body imaging.
Mouse IgG subclass variants of 3BNC117 (mouse IgG1, mouse IgG1 D265A, and mouse IgG2a) with differential capacity to engage mouse FcgRs were administered (intraperitoneal, i.p.) to luciferase reporter mice 24 hr prior to challenge with HIV-1 Cre pseudovirus. Comparison of the in vivo activity of different mouse-human chimeric IgG subclass variants of 3BNC117 revealed that the mouse IgG2a variant exhibited significantly enhanced in vivo protective activity compared to its mouse IgG1 and mouse IgG1 D265A counterparts ( Figures 2B-2D) . Titration of the mAb dose revealed a specific range at which mouse IgG2a exhibits improved in vivo activity; lower doses (<1 mg) were not sufficient to prevent infection, whereas at higher ones (100 mg), Fab-mediated neutralization activity dominates masking any Fc effector contribution by mouse IgG2a subclass variant ( Figure 2C ). Minimal activity was observed in isotype subclass variants of a non-HIV-1 reactive antibody (mGO53 [Wardemann et al., 2003 ]) ( Figure 2E ).
To provide further evidence on the role of Fc-FcgR interactions in the augmented in vivo protective activity of mouse IgG2a subclass variant of 3BNC117, its activity was assessed in two mouse strains (crossed to ROSA-Luc) deficient for all classes of mouse FcgRs: (1 Figure 2F ; Fcer1g Figure 2G ), suggesting the involvement of FcgR-, but not complement-mediated pathways in the enhanced in vivo activity of 3BNC117 mouse IgG2a subclass variant.
Given the selective binding specificity of mouse IgG2a for activating FcgR, like FcgRIV and FcgRI, it is likely that viral opsonization by mouse IgG2a mAbs promotes their clearance by circulating or tissue-resident FcgR-expressing effector cells, contributing thereby to the observed enhanced in vivo activity of mouse IgG2a mAbs. To determine the consequences of mAb-mediated virus opsonization on clearance and subsequent prevention of viral entry, circulating viral content was measured in mice that have been administered either mouse IgG2a or mouse IgG1 D265A (FcgR null binding) variants of 3BNC117. Serum viral RNA was quantified by reverse-transcriptase quantitative PCR, and as it is evident in Figures 2H and 2I , significantly lower viral titers were observed on day 1 and 3 postinfection in mice that have previously received mouse IgG2a 3BNC117 compared to untreated (PBS) or mouse IgG1 D265A-treated ones. These findings suggest that the observed enhancement in FcgR-mediated in vivo protective activity of mouse IgG2a 3BNC117 could be attributed to improved clearance of mAbopsonized viruses prior to infection.
To determine whether the enhanced in vivo activity observed for the mouse IgG2a subclass variant of the broadly neutralizing anti-CD4bs mAb 3BNC117 also extends to mAbs with low neutralization potency, we assayed mouse subclass variants of 1-74, a poorly neutralizing, anti-CD4bs mAb (IC 50 > 50 mg/ml for HIV-1 YU-2 ). Mouse IgG2a 1-74 mAb exhibited significantly augmented in vivo activity compared to mouse IgG1 and mouse IgG1 D265A variants ( Figure 3A )-an effect that was not evident in FcgR-deficient (FcgRa null ) mice ( Figure 3B ). Similar to antiCD4bs mAbs, increased in vivo effector activity of mouse IgG2a subclass variants was observed in mAbs with differential epitope specificities (CD4bs, V1/2, and V3), indicating that augmented FcgR-mediated in vivo protective activity is independent of Fab-antigen interactions relating to epitope targeting ( Figures 3C-3E ). Furthermore, no differences in mAb serum concentration at the time of HIV-1 Cre pseudovirus challenge were observed among the various mouse IgG subclass variants, confirming that the enhanced in vivo activity of mouse IgG2a mAbs could not be attributed to differential mAb biodistribution (Figure S2) . These findings suggest a clear role for Fc effector activity of anti-HIV-1 mAbs in preventing viral entry and revealed that selective engagement of activating, but not inhibitory FcgR by mouse IgG2a subclass mAbs, induces increased in vivo protective activity-an effect not dependent on antibody potency or epitope specificity.
Development of Human IgG1 Anti-HIV-1 bNAbs with Selectively Enhanced FcgR Binding Profile through Fc Domain Engineering
Given our finding using WT mice that preferential engagement of activating, but not inhibitory, FcgRs augmented the in vivo bNAb activity, human IgG1 Fc domain variants of anti-HIV-1 bNAbs (3BNC117, 10-1074 [Mouquet et al., 2012] , and PG16) were generated to selectively engage with enhanced activity human activating FcgRs, like human FcgRIIIa and FcgRIIa, with minimal modulation of FcgRIIb binding capacity ( YU-2 Cre pseudovirus infection) was determined using a qRT-PCR-based assay specific for Cre. Data are presented as the mean ± SEM. *p < 0.05 and **p < 0.01 compared to PBS/mIgG1 D265A groups; n = 4 mice per group. [Smith et al., 2012] ; FcgR null binding: G236R/L328R [GRLR] [Horton et al., 2010] ) of 3BNC117, 10-1074, and PG16 were expressed in mammalian cells and characterized in terms of their affinity and specificity for HIV-1 Env (Figures 4C and S3 and  Table S5 ) and in vitro neutralization ( Figure 4D and Table S6 ).
No differences in their antigen specificity and in vitro neutralization activity were detected among the various Fc domain variants, despite their differential capacity to engage the various human and mouse FcgRs ( Figure 4A and Table S4 ).
Fc-Optimized Variants of Anti-HIV-1 Human IgG1 bNAbs Exhibit Improved In Vivo Activity Although our findings suggest that preferential engagement of activating FcgRs through mouse IgG2a subclass variants modulates the in vivo bNAb activity, the use of a murine model system does not allow direct comparison of mAb Fc effector activity in humans. To overcome this problem, we have recently developed a mouse model in which the mouse FcgRs were deleted and all the human FcgRs were expressed as transgenes, faithfully recapitulating the human-specific FcgR expression pattern and diversity (Smith et al., 2012) . These mice have been previously characterized and successfully used for the study of human IgG Fc effector activity in vivo DiLillo et al., 2014; Smith et al., 2012 at the time of virus challenge irrespective of the Fc variant (Figure S4A) . Furthermore, no in vivo protective activity was observed when a non-HIV-1 reactive mAb (mGO53) was used as control ( Figure 5C ). These findings clearly highlight the contribution of Fc-FcgR interactions in the in vivo mAb activity using a mouse system that closely resembles the unique pattern of human FcgR structural and functional diversity.
In an attempt to provide additional evidence on the importance of Fc effector pathways for the in vivo activity of anti-HIV-1 mAbs, the activity of Fc domain variants of anti-HIV-1 mAbs was evaluated in two different mouse models of HIV-1 infection that recapitulate the complete virus cycle of HIV-1. Human IgG1 Figure 5D ). Concurrent administration of bNAbs targeting different epitopes of HIV-1 Env has been shown to confer sustained suppression of viremia in humanized mouse models of HIV-1 infection (Horwitz et al., 2013; Klein et al., 2012b) . This model has been previously used to evaluate the therapeutic potential of several anti-HIV-1 bNAbs and involves the use of NRG mice reconstituted with human fetal liver-derived CD34 + hematopoietic stem cells (HSCs) (Klein et al., 2012b) . To determine the contribution of the Fc effector function in the in vivo therapeutic activity of broadly neutralizing anti-HIV-1 mAbs, HIV-1 YU-2 -infected humanized mice were treated with a combination of 3BNC117, 10-1074, and PG16 (200 mg per mAb, every 5-7 days) either as GASDALIE or GRLR Fc variants, which exhibit enhanced or diminished FcgR binding capacity, respectively (Table S4) . Both variants exhibited comparable binding capacity to human or mouse FcRn/b2 microglobulin and similar in vivo half-life profile ( Figures S4B-S4F) . In comparison to mice treated with the FcgR null binding (GRLR) variant of 3BNC117, 10-1074, and PG16, GASDALIE-treated mice exhibited faster and sustained reduction in viral load with a significantly higher proportion of them demonstrating durable (lasting > 3 consecutive weeks) viremia suppression (viremia levels below detection limit [<800 copies/ml]) ( Figures 6A-6D ). Sequencing of HIV-1 gp120 from GASDALIE-treated mice that failed to completely suppress viremia (3/12) revealed recurrent mutations in some of the bNAb-recognizing epitopes within gp120 ( Figure S5 ). Furthermore, when we monitored viremia for several weeks (up to 8) following cessation of bNAb treatment in decaying serum anti-HIV-1 bNAb concentration, GASDALIE-treated mice exhibited suppressed viremia even when serum bNAb concentration dropped below 3 mg/ml; an average concentration previously determined when viral rebound occurred in mice treated with the same combination (3BNC117, 10-1074, and PG16) of WT hIgG1 bNAbs (Halper-Stromberg et al., 2014) . In summary, these findings strongly support that the in vivo protective activity of anti-HIV-1 mAbs is highly dependent upon Fc-FcgR interactions and that Fc-optimized bNAb variants with enhanced FcgR binding capacity exhibited improved in vivo protective activity.
DISCUSSION
Since the first clinical use of mAbs for the treatment of inflammatory and neoplastic disorders, it became apparent that Fc effector activity plays an essential role in the therapeutic potential of an antibody (Nimmerjahn and Ravetch, 2012) . For example, the therapeutic outcome of a number of mAbs was associated with allelic variants of FcgR genes that affect the receptor capacity for IgG binding (Nimmerjahn and Ravetch, 2012) . This ever-increasing body of evidence suggests a significant role of FcgR-mediated interactions in the in vivo activity of antibody-based therapeutics. Despite previous evidence on the role of FcgR effector activity in clinical progression of AIDS and mAbmediated pre-exposure prophylaxis (Hessell et al., 2007) , the contribution of Fc effector function to the in vivo activity of anti-HIV-1 bNAbs has not yet been determined, mainly due to the lack of an in vivo model system for HIV-1 entry that recapitulates the unique pattern of human FcgR expression and diversity. Current strategies to measure the neutralization activity of anti-HIV-1 mAbs involve well-established in vitro assays (TZMbl cell-based assays), which generally offer no information on the antibody effector activity because they lack FcgR-expressing effector leukocytes. Likewise, in vitro conditions of assays commonly used for the study of antibody Fc effector activity fail to reproduce the in vivo complexity that governs FcgR-mediated pathways. Nonhuman primates have been widely used for the in vivo study of HIV-1 infection, and a role for Fc effector function in the mAb-mediated antiviral activity has been previously demonstrated (Hessell et al., 2007) . However, given the relative limitations that nonhuman primate models present, the precise role of Fc-FcgR interactions in the neutralizing activity of anti-HIV-1 bNAbs cannot be systematically studied. For example, nonhuman primate models display substantial FcgR genomic variation, and their FcgR functional and structural characteristics are not concordant with human FcgR physiology (Nguyen et al., 2011 ) (S.B. and J.V.R., unpublished data).
It is therefore likely that any evidence on the role of Fc effector activity obtained through the use of in vitro assays or nonhuman primate in vivo models might not represent accurately the complexity and diversity of human FcgR physiology. Indeed, recent studies indicated that the relative contribution of FcgRmediated pathways to the in vivo mAb activity diverges greatly between humans and nonhuman primates, and many mechanistic insights obtained from one species were not replicated to the other. For example, although Fc-engineered glycovariants of b12 (nonfucosylated b12) with enhanced affinity for human and rhesus FcgRIIIa demonstrated substantially improved in vitro Fc effector activity in NK cell activation and ADCC and ADCVI assays using human FcgR-expressing effector leukocytes, there was no augmentation in the capacity of this mAb variant to protect macaques against mucosal SHIV challenge (Moldt et al., 2012) . Similarly, in another study , passive transfer of antibodies failed to protect macaques following SHIV challenge, despite their exceptional in vitro ADCC activity using human-derived effector leukocytes.
To precisely delineate the FcgR-mediated mechanisms that participate in the in vivo activity of anti-HIV-1 bNAbs, we utilized a recently developed mouse model for HIV-1 entry (Pietzsch et al., 2012) , as well as human leukocyte-reconstituted mice, as models for bNAb-mediated therapy. In agreement with previous observations on the requirement of Fc effector activity of anti-HIV-1 mAbs to confer pre-and postexposure prophylaxis in macaques and humanized mice, respectively (Halper-Stromberg et al., Hessell et al., 2007) , our study demonstrated a key role for FcgR-mediated interactions in the in vivo activity of anti-HIV-1 bNAbs. Assessment of the in vivo activity of mouse-human chimeric anti-HIV-1 bNAbs in WT mice revealed significantly augmented activity of mouse IgG2a subclass variants through enhanced opsonization and clearance of viral particles from circulation. These protective effects of mouse IgG2a reflect the capacity of this subclass to interact with activating FcgRs like FcgRIV and FcgRI (Table S1 and Figure 1A) . Indeed, in several mouse models of antibody-mediated cellular cytotoxicity, such differences in the capacity of the various mouse IgG subclasses to engage activating or inhibitory FcgRs have been shown to be predictive of the in vivo mAb activity (Abboud et al., 2010; DiLillo et al., 2014; Li and Ravetch, 2011; Nimmerjahn et al., 2010; Nimmerjahn and Ravetch, 2005) .
Because engagement of activating, but not inhibitory, FcgRs conferred augmented in vivo protective activity, we developed Fc domain variants of human IgG1 to exhibit selectively enhanced binding capacity to activating human FcgRs. As the amino acid backbone of the Fc domain is the main determinant for Fc-FcgR interaction, introduction of certain mutations in the Fc region that participates in the FcgR binding interface modulates the capacity of an IgG molecule to interact with FcgRs (Lazar et al., 2006; Shields et al., 2001 ). This approach has been previously employed by several groups to successfully generate antibodies with improved Fc effector functions, including antibody-dependent cellular cytotoxicity (ADCC) and opsonization through enhancement of Fc-FcgR interactions DiLillo et al., 2014; Heider et al., 2011; Horton et al., 2010; Lazar et al., 2006; Smith et al., 2012) . Similarly, in our study, Fc domain variants (GASDALIE) of anti-HIV-1 bNAbs that exhibited enhanced binding capacity for activating human FcgRs, such as FcgRIIa and FcgRIIIa ( Figures  4A and 4B ), also presented augmented in vivo protective and therapeutic activity compared to WT or FcgR null binding variants (GRLR). Despite the obvious limitations that animal models present to reflect precisely the complexity of human HIV-1 infection (duration of infection, host immune responses, and alterations in effector cellular compartments), our findings strongly support the importance of activating FcgR engagement in the bNAb-mediated antiviral protection. In summary, our findings clearly indicate that the in vivo activity of anti-HIV-1 mAbs is largely determined by Fc domain interactions. Indeed, the in vivo protective activity of anti-HIV mAbs correlates precisely with their capacity to engage activating FcgRs, but not with their in vitro neutralization activity. For example, poorly neutralizing anti-HIV-1 mAbs, like 1-74, exhibit potent in vivo activity when expressed as Fc subclass variants capable for activating FcgR engagement ( Figure 3A) . Likewise, antibodies with exceptionally high neutralization potency readily lose their in vivo therapeutic activity when their capacity for FcgR engagement is diminished (Figure 6 ). These findings highlight the substantial role of FcgR-mediated mechanisms in the in vivo protective activity of anti-HIV-1 bNAbs, completely revising our current understanding of the mechanisms of antibody-mediated viral neutralization. Contrary to the typical notion that viral neutralization by antibodies is simply the result of blocking viral entry via Fab-antigen interactions, our observations strongly suggest that Fc-mediated effector functions contribute substantially to the activity of anti-HIV-1 mAbs.
Understanding the significance of Fc-FcgR interactions in the protective activities of anti-HIV-1 antibodies would provide useful insights for the development of vaccination strategies to elicit antibodies with enhanced capacity to activate FcgR-mediated pathways. Additionally, in view of the recent successful therapeutic application of several anti-HIV-1 mAbs with exceptionally broad and potent neutralizing activity to effectively control viral replication in nonhuman primate (Barouch et al., 2013; Shingai et al., 2013) and humanized mouse models (Horwitz et al., 2013; Klein et al., 2012b) , optimization of their in vivo therapeutic efficacy is necessary to accelerate their potential clinical use for the treatment of HIV-1 infection in humans. Although previously employed strategies to successfully generate anti-HIV bNAbs with increased potency mainly focused on enhancing the specificity and breadth of Fab-antigen interactions , in the present report, we suggest that modifications in the Fc domain to modulate its selective interaction with different FcgRs can greatly influence the protective activity of bNAbs. These findings suggest strategies for designing and developing therapeutic antibodies with improved in vivo efficacy for the prevention and treatment of HIV-1 infection in humans.
EXPERIMENTAL PROCEDURES
A detailed description of the experimental procedures is provided in the Extended Experimental Procedures section.
In Vivo HIV-1 Pseudovirus Infection and Bioluminescence Imaging Mice were injected with 10 11 adenoviral particles i.v. 48 hr prior to infection with HIV-1 Cre pseudovirus. For in vivo infection, HIV-1 YU-2 pseudovirus (3-5.5 3 10 10 ) was injected through the lateral vein.
On day 4 postinfection with pseudovirus, mice were anesthetized with 2% (v/v) isoflurane and injected i.p. with 4.5 mg D-Luciferin (Regis Technologies). For FcgR humanized mice, mice were anesthetized with 2% (v/v) isoflurane and ketamine/xylazine (75 mg and 15 mg/kg of body weight, respectively; i.p.), and the peritoneal cavity was surgically exposed prior to in vivo imaging. Bioluminescence was acquired using an IVIS Lumina II platform (Caliper Life Sciences), and data were analyzed using Living Image imaging software (Caliper Life Sciences). Figure S5 ). Quantitation of serum bNAb concentration (right axis, red line) following cessation of antibody therapy revealed sustained viremia suppression in GASDALIE-treated mice at limiting anti-HIV-1 bNAb serum levels. (C and D) Comparison of their in vivo therapeutic activity revealed that GASDALIE mAb variants induced a significant and faster reduction in viral load (C), resulting in substantially lower proportion of mice with viremia levels above the detection limit (>800 copies/ml). (D) n = 12 per group; **p < 0.05 and ***p < 0.01 GASDALIE versus GRLR-treated groups. See also Figure S5 .
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Viral Load Quantification
For the quantification of serum HIV-1 YU-2 Cre pseudovirus levels, viral RNA was purified from serum (100 ml), and Cre RNA content of the samples was quantitated by one-step real time RT-PCR. Plasma HIV-1 viral load was quantified as previously described (Horwitz et al., 2013; Klein et al., 2012b) . The lower limit of detection for this assay was previously determined to be 800 copies/ml (Klein et al., 2012b) . Additional details are presented in the Extended Experimental Procedures section.
In Vitro HIV-1 Infection of CD4 + T Cells
Human PBMCs were purified from peripheral blood leukocyte units (New York Blood Center) using Ficoll density gradient medium (Ficoll-Paque Plus, GE Healthcare), followed by isolation of CD4 + T cells by negative magnetic immunoselection (human CD4 + T cell isolation kit [negative selection], Miltenyi Biotech). Purified CD4 + T cells (5 3 10 6 cells/ml in complete RPMI media)
were stimulated with PHA (5 mg/ml; Sigma) and recombinant human IL-2 (50 U/ml; Peprotech) for 48 hr prior to infection with HIV-1 YU-2 (50 ng p24/ 10 7 cells for 4 hr). Following infection, cells were incubated in fresh complete RPMI media, supplemented with IL-2 (50 U/ml) for 60 hr. Prior to injection (2 3 10 7 , i.v.) to NRG mice, cells were washed twice in PBS.
In Vivo HIV-1 Infection and mAb Treatment Humanized NRG mice were generated by intrahepatic human CD34 + HSCs injection of sublethally irradiated neonatal NRG mice, as previously described (Horwitz et al., 2013; Klein et al., 2012b) . Mice (>10 weeks) with a measurable human CD45 + graft were infected following i.p. injection of HIV-1 YU-2 (57.5 ng p24). Viral load was quantified 3 weeks postinfection, and mice with viral loads > 10 4 copies/ml were included in treatment experiments. Antibodies (3BNC117, 10-1074, PG16, 200 mg of each mAb, 600 mg total in PBS containing 2 mg IVIG, Gammagard) were administered subcutaneously (s.c.) every 5 days for the first 2 weeks and weekly thereafter for 6 weeks. This dosing schedule was sufficient to maintain serum levels of each mAb > 10 mg/ml over the course of the treatment ( Figure S4F ). IVIG (5 mg) was administered s.c. 6 hr prior to the first antibody injection. No neutralization activity or gp140 reactivity was observed for the IVIG preparation, as assessed by TZMbl assay and anti-gp140 ELISA, respectively.
Statistical Analysis
Results from multiple experiments are presented as mean ± SEM. One-way ANOVA or Kruskal-Wallis test was used to test for differences in the mean values of quantitative variables, and where statistically significant effects were found, post hoc analysis using Bonferroni t test or Dunn's multiple comparison test was performed, respectively. For infection curve comparison, viremia rates (sustained aviremia was defined as VL < 800 copies/ml for > 3 consecutive weeks) were analyzed with the log rank (Mantel-Cox) test. Data were analyzed with Graphpad Prism software (Graphpad) and p values of < 0.05 were considered to be statistically significant.
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